Institutional Investors Are Buying Charming Shoppes Inc (NASDAQ:CHRS)

Coherus BioSciences, Inc. (NASDAQ:CHRS) Logo

Sentiment for Charming Shoppes Inc (NASDAQ:CHRS)

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment increased to 1.5 in 2019 Q1. Its up 0.21, from 1.29 in 2018Q4. The ratio has improved, as 57 hedge funds opened new or increased holdings, while 38 sold and reduced positions in Charming Shoppes Inc. The hedge funds in our partner’s database now own: 62.32 million shares, up from 59.12 million shares in 2018Q4. Also, the number of hedge funds holding Charming Shoppes Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 25 Increased: 34 New Position: 23.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $1.50 billion. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

The stock increased 0.66% or $0.13 during the last trading session, reaching $19.83. About 748,418 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 6.56% since September 10, 2018 and is downtrending. It has underperformed by 6.56% the S&P500.

Analysts await Coherus BioSciences, Inc. (NASDAQ:CHRS) to report earnings on November, 14. They expect $0.36 EPS, up 141.38 % or $1.23 from last year’s $-0.87 per share. CHRS’s profit will be $27.23M for 13.77 P/E if the $0.36 EPS becomes a reality. After $0.32 actual EPS reported by Coherus BioSciences, Inc. for the previous quarter, Wall Street now forecasts 12.50 % EPS growth.

Ghost Tree Capital Llc holds 1.66% of its portfolio in Coherus BioSciences, Inc. for 450,000 shares. Hound Partners Llc owns 1.96 million shares or 1.15% of their US portfolio. Moreover, Sivik Global Healthcare Llc has 1.13% invested in the company for 225,000 shares. The Connecticut-based Pier Capital Llc has invested 1.11% in the stock. Pura Vida Investments Llc, a New York-based fund reported 165,613 shares.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Ratings analysis reveals 100% of Coherus BioSciences’s analysts are positive. Out of 3 Wall Street analysts rating Coherus BioSciences, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $28 while the high is $4300. The stock’s average target of $33.67 is 69.79% above today’s ($19.83) share price. CHRS was included in 6 notes of analysts from May 7, 2019. The firm has “Buy” rating by Robert W. Baird given on Wednesday, June 19. The rating was maintained by Barclays Capital with “Buy” on Friday, June 21.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Nasdaq.com which released: “Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates – Nasdaq” on August 01, 2019, also Globenewswire.com with their article: “Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer – GlobeNewswire” published on March 18, 2019, Globenewswire.com published: “Coherus BioSciences and Amgen Settle Trade Secrets Action – GlobeNewswire” on May 02, 2019. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Nasdaq.com and their article: “Coherus (CHRS) Catches Eye: Stock Jumps 6.9% – Nasdaq” published on April 09, 2019 as well as Seekingalpha.com‘s news article titled: “Piper sees 36% upside in Cronos Group in premarket analyst action – Seeking Alpha” with publication date: August 13, 2019.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.